Additional information
| Active substance | Cagrilintide acetate |
|---|---|
| Water Retention | Minimal to none |
| Hepatotoxicity | No significant hepatotoxic effects reported |
| Lab Test | Specific tests for monitoring levels not commonly used in clinical practice |
| Also known as | No alternative names reported |
| Blood pressure | Can potentially lower blood pressure due to weight loss effects |
| Trade name | Not marketed under a specific trade name yet |
| FORM | 1 vial x 10 mg |
| Storage conditions | Store in a refrigerator, protect from light |
| Chemical name | Cagrilintide acetate |
| Formula | Not specified |
| Substance class | Peptide analog |
| Main action | Reduces appetite and enhances weight loss |
| Half-life | Approximately 7 days |
| Dosage (medical) | Typically administered as a subcutaneous injection, dosage varying depending on clinical trial phase and specific medical guidelines |
| Dosage (sports) | Not applicable as not typically used in sports settings |
| Effects | Promotes weight loss, reduces caloric intake, improves glycemic control |
| Side effects | Potential for gastrointestinal disturbances, injection site reactions, and nausea |
| Use in sports | Not commonly used for sports enhancement |
| Manufacturer | Dragon Pharma |
Reviews
There are no reviews yet.